Cost analysis of second-line therapies for platinum-refractory ovarian cancer: Reimbursement dilemmas for medicare patients

Cancer Investigation

Volumn 17, Issue 8, 1999, Pages 559-565

  Stinson, Tammy J ^c   Calhoun, Elizabeth ^c   Yang, Teresa ^c   Lurain, John R ^a   Bennett, Charles L ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b JESSE BROWN VA MEDICAL CENTER   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALTRETAMINE; CHLORPROMAZINE; DEXAMETHASONE; DIPHENHYDRAMINE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IBUPROFEN; LORAZEPAM; METOCLOPRAMIDE; PACLITAXEL; PROCHLORPERAZINE MALEATE; RANITIDINE; TOPOTECAN;

ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DRUG COST; DRUG SAFETY; HEALTH CARE POLICY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MEDICARE; NAUSEA; NEUTROPENIA; ORAL DRUG ADMINISTRATION; OVARY CANCER; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REIMBURSEMENT; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; VOMITING;

EID: 0032697257     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357909909032840     Document Type: Article

References (27)

1. Parker SL, Tong T, Bolden S, et al: Cancer Statistics, 1996. Cancer Statistics 46:10-11, 1996.
2. Thigpen J, Blessing JA, Vance RB, et al: Chemotherapy in ovarian carcinoma: present role and future prospects. Semin Oncol 16: 58-65, 1989.
3. Thigpen J, Vance RB, Khansur T: Second-line chemotherapy for recurrent carcinoma of the ovary. Cancer 71:1559-1564, 1993.
4. McKeage MJ: Comparative adverse effect profiles of platinum drugs. Drug Saf 13:228-44, 1995.
5. Ozols RF, Rubin SC, Dembo AJ, et al: Epithelial Ovarian Cancer. Philadelphia, J.B. Lippincott, 1992, pp. 731-732.
6. McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334: 1-6, 1996.
7. Markman M, Rothman R, Hakes T, et al: Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9:389-393, 1991.
8. Eisenhauer EA, ten Bokken Huinink WW, Swenertokn KD, et al: European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 12:2654-2666, 1994.
9. Aravantinos G, Skarlos DV, Kosmidis P, et al: A phase II study of paclitaxel in platinum pretreated ovarian cancer. A Hellenic Cooperative Oncology Group Study. Eur J Cancer 33:160-163, 1997.
10. Bruzzone M, Catsafados E, Miflietta L, et al: Salvage chemotherapy with paclitaxel in platinum-resistant advanced ovarian cancer patients. Oncology 53:349-53, 1996.
11. Gore ME, Levy V, Rustin G, et al: Paclitaxel in relapsed and refractory ovarian cancer: the UK and Eire experience. Br J Cancer 72:1016-1019, 1995.
12. Nardi M, Aloe A, DeMarco S, et al: Paclitaxel as salvage therapy in advanced pretreated ovarian cancer: a phase II study. Am J Clin Oncol 20:230-232, 1997.
13. Ten Bokkel Huinink W, Gore M, Carmichael J, et al: Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 15:2183-2193, 1997.
14. Creemers GJ, Bolis G, Gore M, et al: Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large european phase II study. J Clin Oncol 14:3056-3061, 1996.
15. Kudelka AP, Tresukosol D, Edwards CL, et al: A phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 14:1552-1557, 1996.
16. Vergote I, Himmelmann A, Frankendal B, et al: Hexamethylmelamine as second-line therapy in platin resistant ovarian cancer. Gynecol Oncol 47:282-286, 1992.
17. Manetta A, MacNeill C, Lyter JA, et al: Hexamethylmelamine as a single second line agent in ovarian cancer. Gynecol Oncol 36: 93-96, 1990.
18. Schink J, Harris L, Grosen E, et al: Altretamine an effective salvage chemotherapy after paclitaxel in women with recurrent platinum resistant ovarian cancer. Proc Am Soc Clin Oncol 14:770a, 1995.
19. Hoskins PJ, Swenerton KD: Oral etoposide is active against platinum-resistant epithelial ovarian cancer. J Clin Oncol 12:60-63, 1994.
20. Rose PG, Blessing JA, Mayer AR, et al: Prolonged oral etoposide as second line therapy for platinum resistant and platinum sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 16:405-410, 1998.
21. Medical Carriers Manual: Drugs and Supplies, HCFA Pub. 6 Section 2049.5 Coverage and Limitations, 2-18.22, 05-96.
22. Liu G, Franssen E, Fitch MI, et al: Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15:110-115, 1997.
23. Bailes J: Health Care Economics of Cancer in the Elderly. Cancer 80:1348-1350, 1997.
24. Coleman T: Practical Tips for the Practicing Oncologist. Alexandria, Va, American Society of Clinical Oncology, 1997.
25. Federal Register. Vol. 61, No. 227; Fri Nov 22, 1996.
26. Doyle C, Stockler M, Pintilie M, et al: Resource implications of palliative chemotherapy for ovarian cancer. J Clin Oncol 15: 1000-1007, 1997.
27. Ignoffo RJ: Medicare reimbursement for oral antiemetics in management of chemotherapy-induced emesis. Am J Health Syst Pharm 54:830-831, 1997.